A major milestone on March 14th 2025 advanced the EU Trilogue discussions aimed to complete the final text of the New Genomic Techniques (NGTs) or gene editing legislation for the EU; California Rice Commission approved Cibus' field research proposal marking the first time gene edited Rice has been authorized for planting within the state Advancing Rice herbicide tolerance trait commercialization efforts: affirmed strategic collaboration with Albaugh LLC and RTDC Corporation Limited continues to strengthen ...

Legislation aims to adapt EU law to reflect scientific and technological progress, enabling the products of New Genomic Techniques (NGTs), such as gene editing, to contribute to more sustainable agriculture, climate resilience, and food security Proposed legislation identifies a ‘conventional-like’ category of NGT-1 products that would be regulated as conventional varieties, bringing EU regulation closer to that of other global trading partners The agreement on the Council's negotiating mandate allows its ...

Legislation aims to adapt EU law to reflect scientific and technological progress, enabling the products of New Genomic Techniques (NGTs), such as gene editing, to contribute to more sustainable agriculture, climate resilience, and food security Proposed legislation identifies a ‘conventional-like' category of NGT-1 products that would be regulated as conventional varieties, bringing EU regulation closer to that of other global trading partners The agreement on the Council's negotiating mandate allows its ...

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2024 financial results on Thursday, March 20, 2025. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Titl ...

Core Insights - Cibus has demonstrated promising results in its third mode of action for Sclerotinia resistance in canola, which is expected to help preserve crop yields and reduce fungicide usage for farmers [1][4] - The company's Rapid Trait Development System™ (RTDS) allows for efficient gene editing and development of plant traits that are indistinguishable from conventional breeding [2][7] - Cibus has completed edits in four modes of action for Sclerotinia resistance and anticipates completing field tests by the end of 2025 [3] Company Overview - Cibus is a technology company focused on gene editing to develop and license traits to seed companies, addressing productivity and sustainability challenges in agriculture [6][7] - The company is not a seed company but rather licenses its traits for royalties on seed sales, with a focus on major global row crops like canola, rice, and soybean [7] - Cibus aims to develop traits at a fraction of the time and cost compared to conventional breeding, with a current pipeline that includes productivity traits for weed management and disease resistance [7] Industry Context - Sclerotinia sclerotiorum is a significant fungal pathogen affecting canola and other crops, causing yield losses of 7-15% and potentially up to 90% in severe cases [5] - The economic impact of diseases and pests in agriculture is estimated to cost the global economy approximately $300 billion annually, highlighting the importance of Cibus' innovations [6][7] - The development of durable resistance traits is crucial as climate change continues to affect crop diseases and their geographic distribution [4][5]

Initial bioassay data for Cibus' third mode of action for white mold (Sclerotinia) resistance trait in canola shows promising results in controlled environment assessment Cibus' white mold resistance traits are expected to help preserve crop yields and reduce fungicide usage for farmers SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that ...

Core Points - Cibus, Inc. announced leadership changes as part of its succession planning strategy, with Rory Riggs resigning as CEO and Peter Beetham appointed as Interim CEO [1][2] - The Board of Directors will search for a permanent CEO, considering both internal and external candidates [2] - Rory Riggs will remain as Chairman of the Board and expressed confidence in the leadership team during the transition [3] Company Overview - Cibus is a leading agricultural technology company focused on developing and licensing plant traits to seed companies for royalties, addressing productivity and sustainability challenges in agriculture [4] - The company utilizes its proprietary Rapid Trait Development System™ (RTDS®) for gene editing, aiming to develop traits more efficiently than conventional breeding methods [4] - Cibus has a pipeline of five productivity traits, including weed management in rice and disease resistance, which are its near-term focus [4]

SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today issued a correction relating to the rice conversion rates previously disclosed in its January 16, 2025 press release. The Company has concluded that the gene editing conversion rates of 10-25% in Rice have not been reconfirmed based upon subsequent experiments and high variability in the co ...

EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simo ...

SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer, will host a presentation at the Sidoti Micro Cap Conference. Presentation detailsDate: Thursday, Januar ...